{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:43:09Z","timestamp":1794807789826,"version":"4.9.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["16-RHUS-0006"],"award-info":[{"award-number":["16-RHUS-0006"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-23-CE14-0091"],"award-info":[{"award-number":["ANR-23-CE14-0091"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["18-CE15-0024-03 NASHILCCD8"],"award-info":[{"award-number":["18-CE15-0024-03 NASHILCCD8"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-0046"],"award-info":[{"award-number":["ANR-10-LABX-0046"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["FRM EQU202203014650"],"award-info":[{"award-number":["FRM EQU202203014650"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.atherosclerosis.2024.119054","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T20:54:10Z","timestamp":1731704050000},"page":"119054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics"],"prefix":"10.1016","volume":"400","author":[{"given":"Emily","family":"Flam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel T.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6262-1126","authenticated-orcid":false,"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2024.119054_bib1","article-title":"National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature","author":"Lee","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2018.73155","article-title":"The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases","volume":"4","author":"W\u00f3jcik-Cichy","year":"2018","journal-title":"Clin. Exp. Hepatol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.119054_bib4","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of us and global data from the American heart association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"issue":"10440","key":"10.1016\/j.atherosclerosis.2024.119054_bib5","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.119054_bib6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/hep4.1822","article-title":"TM6SF2: a novel genetic player in nonalcoholic fatty liver and cardiovascular disease","volume":"6","author":"Luo","year":"2021","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s12876-021-02020-z","article-title":"PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD","volume":"21","author":"Akuta","year":"2021","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib10","first-page":"dgae264","article-title":"LDL-C and TC mediate the risk of PNPLA3 inhibition on cardiovascular diseases","author":"Zhang","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119054_bib11","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119054_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"TouchREVIEWS Endocrinol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.119054_bib15","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3350\/cmh.2021.0127","article-title":"Recent advances in nonalcoholic fatty liver disease metabolomics","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Mol. Hepatol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101432","article-title":"Concise review of lipidomics in nonalcoholic fatty liver disease","volume":"49","author":"B\u00e9land-Bonenfant","year":"2023","journal-title":"Diabetes Metab."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119054_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s44161-023-00270-6","article-title":"Metabolite signaling in the heart","volume":"2","author":"Flam","year":"2023","journal-title":"Nat. Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib19","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2018.03.055","article-title":"Metabolomics and isotope tracing","volume":"173","author":"Jang","year":"2018","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.119054_bib20","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatol. Baltim. Md"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib22","doi-asserted-by":"crossref","DOI":"10.2337\/db08-1074","article-title":"Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver","volume":"58","author":"Kotronen","year":"2009","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1194\/jlr.P056002","article-title":"Biomarkers of NAFLD progression: a lipidomics approach to an epidemic1","volume":"56","author":"Gorden","year":"2015","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.2040-4603.2018.tb00008.x","article-title":"Triglyceride metabolism in the liver","volume":"8","author":"Alves-Bezerra","year":"2017","journal-title":"Compr. Physiol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.119054_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022775","article-title":"Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model","volume":"6","author":"Gorden","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2024.119054_bib26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(20)30186-2","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056159","volume":"12","author":"Amin","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00726-014-1894-9","article-title":"Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease","volume":"47","author":"Lake","year":"2015","journal-title":"Amino Acids"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cmet.2006.03.007","article-title":"The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis","volume":"3","author":"Li","year":"2006","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/srep46658","article-title":"Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients","volume":"7","author":"Chiappini","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1139\/apnm-2012-0261","article-title":"Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine","volume":"38","author":"Arendt","year":"2013","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib32","first-page":"105","article-title":"Essential phospholipids in fatty liver: a scientific update","volume":"9","author":"Gundermann","year":"2016","journal-title":"Clin. Exp. Gastroenterol."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","article-title":"Mechanisms and regulation of cholesterol homeostasis","volume":"21","author":"Luo","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of cholesterol\u2010associated steatohepatitis in the development of NASH","volume":"6","author":"Horn","year":"2021","journal-title":"Hepatol. Commun."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib35","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2021.07.025","article-title":"Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention","volume":"75","author":"Lange","year":"2021","journal-title":"J. Hepatol."},{"issue":"9756","key":"10.1016\/j.atherosclerosis.2024.119054_bib36","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet Lond. Engl."},{"issue":"Jan","key":"10.1016\/j.atherosclerosis.2024.119054_bib37","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib38","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/hep.28953","article-title":"Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease","volume":"65","author":"Hall","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/liv.12685","article-title":"Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis","volume":"35","author":"Yamada","year":"2015","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib41","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/hep.27695","article-title":"Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids","volume":"61","author":"Arendt","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jhep.2007.09.009","article-title":"Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study","volume":"48","author":"Allard","year":"2008","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12944-017-0450-5","article-title":"Hydroxytyrosol prevents reduction in liver activity of \u0394-5 and \u0394-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice","volume":"16","author":"Valenzuela","year":"2017","journal-title":"Lipids Health Dis."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1194\/jlr.M001966","article-title":"A subset of dysregulated metabolic and survival genes is associated with severity of hepatic steatosis in obese Zucker rats","volume":"51","author":"Buqu\u00e9","year":"2010","journal-title":"J. Lipid Res."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.119054_bib45","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2024.119054_bib46","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1194\/jlr.R120000800","article-title":"Roles of polyunsaturated fatty acids, from mediators to membranes","volume":"61","author":"Harayama","year":"2020","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib47","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11745-015-4091-z","article-title":"Low n-6\/n-3 PUFA ratio improves lipid metabolism, inflammation, oxidative stress and endothelial function in rats using plant oils as n-3 fatty acid source","volume":"51","author":"Yang","year":"2016","journal-title":"Lipids"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/01.CIR.0000079224.46084.C2","article-title":"Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women","volume":"108","author":"Pischon","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.119054_bib51","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1161\/STROKEAHA.107.509455","article-title":"Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients","volume":"39","author":"Tanaka","year":"2008","journal-title":"Stroke"},{"issue":"Aug","key":"10.1016\/j.atherosclerosis.2024.119054_bib52","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3350\/cmh.2017.0103","article-title":"NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs","volume":"23","author":"Caldwell","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/143109","article-title":"Omega-3 polyunsaturated fatty acids: the way forward in times of mixed evidence","volume":"2015","author":"Weylandt","year":"2015","journal-title":"BioMed Res. Int."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib55","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/hep.27289","article-title":"Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome\u2217 study","volume":"60","author":"Scorletti","year":"2014","journal-title":"Hepatol. Baltim. Md"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119054_bib56","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/CS20030326","article-title":"Increase in long-chain polyunsaturated fatty acid n - 6\/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease","volume":"106","author":"Araya","year":"2004","journal-title":"Clin. Sci. Lond. Engl."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib59","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.119054_bib60","first-page":"1983","article-title":"Acetyl-CoA carboxylase inhibitor GS-0976 for 12 Weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis","volume":"16","author":"Lawitz","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib61","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib62","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/CIRCRESAHA.123.323284","article-title":"VLDL biogenesis and secretion: it takes a village","volume":"134","author":"Van Zwol","year":"2024","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1743-7075-7-35","article-title":"Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion","volume":"7","author":"Sundaram","year":"2010","journal-title":"Nutr. Metab."},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00125-005-0125-z","article-title":"Overproduction of large VLDL particles is driven by increased liver fat content in man","volume":"49","author":"Adiels","year":"2006","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib65","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1053\/jhep.2002.32527","article-title":"Apolipoprotein synthesis in nonalcoholic steatohepatitis","volume":"35","author":"Charlton","year":"2002","journal-title":"Hepatol. Baltim. Md"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119054_bib66","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jhep.2012.07.030","article-title":"Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro","volume":"57","author":"Pirazzi","year":"2012","journal-title":"J. Hepatol."},{"issue":"24","key":"10.1016\/j.atherosclerosis.2024.119054_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144079","article-title":"Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans","volume":"5","author":"Bor\u00e9n","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.119054_bib68","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","article-title":"Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease","volume":"152","author":"Ch\u00e1vez-Talavera","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib69","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cmet.2020.02.006","article-title":"Microbiome modulation of the host adaptive immunity through bile acid modification","volume":"31","author":"Kuipers","year":"2020","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib70","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatol. Baltim. Md"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.119054_bib71","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2024-100074","article-title":"Bile acids regulation of cellular stress responses in liver physiology and diseases","volume":"2","author":"Li","year":"2024","journal-title":"eGastroenterology"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib73","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.taap.2013.01.022","article-title":"Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease","volume":"268","author":"Lake","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib74","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1124\/mol.107.039370","article-title":"Activation of nuclear factor (Erythroid-2 like) factor 2 by toxic bile acids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress","volume":"72","author":"Tan","year":"2007","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","article-title":"Bile acids induce inflammatory genes in hepatocytes","volume":"178","author":"Allen","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"14","key":"10.1016\/j.atherosclerosis.2024.119054_bib76","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J. Gastroenterol. WJG"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119054_bib77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/MEG.0b013e3282f4710a","article-title":"Bile acid levels are increased in the liver of patients with steatohepatitis","volume":"20","author":"Aranha","year":"2008","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.119054_bib78","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1021\/pr200629p","article-title":"A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations","volume":"10","author":"Garc\u00eda-Ca\u00f1averas","year":"2011","journal-title":"J. Proteome Res."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2024.119054_bib79","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/oby.22627","article-title":"Ratio of conjugated chenodeoxycholic to muricholic acids is associated with severity of nonalcoholic steatohepatitis","volume":"27","author":"Chen","year":"2019","journal-title":"Obesity"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2024.119054_bib80","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"10","key":"10.1016\/j.atherosclerosis.2024.119054_bib81","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.119054_bib82","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.atherosclerosis.2024.119054_bib83","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MOL.0000000000000597","article-title":"Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell?","volume":"30","author":"Ch\u00e1vez-Talavera","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"issue":"9972","key":"10.1016\/j.atherosclerosis.2024.119054_bib84","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet Lond. Engl."},{"issue":"10215","key":"10.1016\/j.atherosclerosis.2024.119054_bib85","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib86","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jhep.2023.07.014","article-title":"Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis","volume":"79","author":"Sanyal","year":"2023","journal-title":"J. Hepatol."},{"issue":"17","key":"10.1016\/j.atherosclerosis.2024.119054_bib87","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.282.17.1659","article-title":"Alterations in liver ATP homeostasis in human nonalcoholic SteatohepatitisA pilot study","volume":"282","author":"Cortez-Pinto","year":"1999","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib88","first-page":"466","article-title":"Hepatic ATP reserve and efficiency of replenishing: comparison between obese and nonobese normal individuals","volume":"98","author":"Nair","year":"2003","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib89","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/1389557515666150722102613","article-title":"Creatine and the liver: metabolism and possible interactions","volume":"16","author":"Barcelos","year":"2016","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.595371","article-title":"Oxidative stress in non-alcoholic fatty liver disease. An updated mini review","volume":"8","author":"Delli Bovi","year":"2021","journal-title":"Front. Med."},{"issue":"15\u201316","key":"10.1016\/j.atherosclerosis.2024.119054_bib91","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cca.2011.04.013","article-title":"The role of oxidative stress in non-alcoholic steatohepatitis","volume":"412","author":"Koek","year":"2011","journal-title":"Clin. Chim. Acta Int. J. Clin. Chem."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2024.119054_bib92","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.livres.2020.05.003","article-title":"Dysregulation of glutathione synthesis in liver disease","volume":"4","author":"Lu","year":"2020","journal-title":"Liver Res"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2024.119054_bib93","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/antiox7050062","article-title":"Glutathione: antioxidant properties dedicated to nanotechnologies","volume":"7","author":"Gaucher","year":"2018","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2024.119054_bib94","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-1007167","article-title":"Role of the Liver in Interorgan Homeostasis of Glutathione and Cyst(e)ine","volume":"18","author":"Ookhtens","year":"1998","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1124275","article-title":"Glutathione: pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease","volume":"10","author":"Santacroce","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/tgh.2018.07.06","article-title":"Branched-chain amino acids in liver diseases","volume":"3","author":"Tajiri","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2024.119054_bib97","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2174\/1573399815666190502113632","article-title":"The emerging role of branch chain amino acids in the prediction of diabetes: a brief review","volume":"16","author":"Nawaz","year":"2020","journal-title":"Curr. Diabetes Rev."},{"issue":"1","key":"10.1016\/j.atherosclerosis.2024.119054_bib98","doi-asserted-by":"crossref","first-page":"250S","DOI":"10.1093\/jn\/136.1.250S","article-title":"Branched-chain amino acid catabolism in exercise and liver disease","volume":"136","author":"Shimomura","year":"2006","journal-title":"J. Nutr."},{"key":"10.1016\/j.atherosclerosis.2024.119054_bib99","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-physiol-020518-114455","article-title":"Branched chain amino acids","volume":"81","author":"Neinast","year":"2019","journal-title":"Annu. Rev. Physiol."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2024.119054_bib100","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1210\/clinem\/dgaa175","article-title":"Plasma BCAA changes in patients with NAFLD are sex dependent","volume":"105","author":"Grzych","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024012267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915024012267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:27:57Z","timestamp":1777440477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915024012267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":100,"alternative-id":["S0021915024012267"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119054","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver metabolism in human MASLD: A review of recent advancements using human tissue metabolomics","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119054"}}